These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 17259256

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK, Chiang AK, Chan GC, Ha SY.
    Cochrane Database Syst Rev; 2014 Aug 14; (8):CD006945. PubMed ID: 25121561
    [Abstract] [Full Text] [Related]

  • 5. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH.
    J Clin Oncol; 2001 Feb 01; 19(3):697-704. PubMed ID: 11157020
    [Abstract] [Full Text] [Related]

  • 6. Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
    Depreter B, Stove V, Delanghe J.
    Clin Biochem; 2016 Dec 01; 49(18):1390-1395. PubMed ID: 27129796
    [Abstract] [Full Text] [Related]

  • 7. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK, Chiang AK, Chan GC, Ha SY.
    Cochrane Database Syst Rev; 2010 Jun 16; (6):CD006945. PubMed ID: 20556770
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
    De Angelis S, Noce A, Di Renzo L, Cianci R, Naticchia A, Giarrizzo GF, Giordano F, Tozzo C, Splendiani G, De Lorenzo A.
    Eur Rev Med Pharmacol Sci; 2007 Jun 16; 11(3):179-84. PubMed ID: 17970234
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD.
    Pharmacotherapy; 2006 Jun 16; 26(6):806-12. PubMed ID: 16716134
    [Abstract] [Full Text] [Related]

  • 15. Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
    Kimura K, Kanehira N, Takayanagi R, Minohara H, Homma M, Yamada Y.
    Biol Pharm Bull; 2016 Jun 16; 39(5):705-11. PubMed ID: 27150142
    [Abstract] [Full Text] [Related]

  • 16. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN, Shanholtz CB, Thompson JL.
    Ann Pharmacother; 2010 Oct 16; 44(10):1529-37. PubMed ID: 20841516
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M, Shord SS, Haaf CM.
    J Clin Pharm Ther; 2009 Apr 16; 34(2):207-13. PubMed ID: 19250141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.